|Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer|
|Liu, Rui1,2; Chen, Xi1,2; Du, Yiqi4; Yao, Weiyan4; Shen, Lin5; Wang, Cheng1,2,6; Hu, Zhibin7; Zhuang, Rui1,2; Ning, Guang4; Zhang, Chunni6; Yuan, Yaozong4; Li, Zhaoshen3; Zen, Ke1,2; Ba, Yi1,2; Zhang, Chen-Yu1,2|
|WOS标题词||Science & Technology|
|类目[WOS]||Medical Laboratory Technology|
|研究领域[WOS]||Medical Laboratory Technology|
|关键词[WOS]||CIRCULATING MICRORNAS ; CARCINOMA ; SIGNATURE ; ANTIGENS ; RISK ; PCR|
BACKGROUND: Detection of pancreatic cancer (PaC), particularly at early stages, remains a great challenge owing to lack of specific biomarkers. We sought to identify a PaC-specific serum microRNA (miRNA) expression profile and test its specificity and sensitivity as a biomarker in the diagnosis and prognosis of PaC.
METHODS: We obtained serum samples from 197 PaC cases and 158 age-and sex-matched cancer-free controls. We screened the differentially expressed serum miRNAs with Illumina sequencing by synthesis technology using pooled serum samples followed by RT-qPCR validation of a large number of samples arranged in multiple stages. We used risk score analysis to evaluate the diagnostic value of the serum miRNA profiling system. To assess the serum miRNA-based biomarker accuracy in predicting PaC, we performed additional double-blind testing in 77 PaC cases and 52 controls and diagnostic classification in 55 cases with clinically suspected PaC.
RESULTS: After the selection and validation process, 7 miRNAs displayed significantly different expression levels in PaC compared with controls. This 7 miRNA-based biomarker had high sensitivity and specificity for distinguishing various stages of PaC from cancer-free controls and also accurately discriminated PaC patients from chronic pancreatitis (CP) patients. Among the 7 miRNAs, miR-21 levels in serum were significantly associated with overall PaC survival. The diagnostic accuracy rate of the 7-miRNA profile was 83.6% in correctly classifying 55 cases with clinically suspected PaC.
CONCLUSIONS: These data demonstrate that the 7 miRNA-based biomarker can serve as a novel noninvasive approach for PaC diagnosis and prognosis. (C) 2011 American Association for Clinical Chemistry
|作者单位||1.Tianjin Med Univ, Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China|
2.Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Jiangsu, Peoples R China
3.Second Mil Med Univ, Shanghai Changhai Hosp, Shanghai, Peoples R China
4.Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai 200030, Peoples R China
5.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Minist Educ, Key Lab Carcinogenesis & Translat Res,Dept GI Onc, Beijing 100871, Peoples R China
6.Nanjing Univ, Sch Clin, Coll Med, Dept Biochem,Jinling Hosp, Nanjing 210093, Jiangsu, Peoples R China
7.Nanjing Med Univ, Ctr Canc, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China
|Liu, Rui,Chen, Xi,Du, Yiqi,et al. Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer[J]. CLINICAL CHEMISTRY,2012,58(3):610-618.|
|APA||Liu, Rui.,Chen, Xi.,Du, Yiqi.,Yao, Weiyan.,Shen, Lin.,...&Zhang, Chen-Yu.(2012).Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer.CLINICAL CHEMISTRY,58(3),610-618.|
|MLA||Liu, Rui,et al."Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer".CLINICAL CHEMISTRY 58.3(2012):610-618.|